FDA Drug Safety Alerts: SSRI / PPHN

This public health advisory was issued by the FDA on July 19, 2006, in response to two studies of pregnant women who had been treated with selective serotonin reuptake inhibitors (SSRIs). Click here to read the full FDA release, “Public Health Advisory: Treatment Challenges of Depression in Pregnancy and the Possibility of Persistent Pulmonary Hypertension in Newborns.”


Information for Healthcare Professionals: Paroxetine (marketed as Paxil)

FDA ALERT [7/2006]: Increased Risk of Neonatal Persistent Pulmonary Hypertension

A recently published case-control study has shown that infants born to mothers who took selective serotonin reuptake inhibitors (SSRIs) after the 20th week of pregnancy were 6 times more likely to have persistent pulmonary hypertension (PPHN) than infants born to mothers who did not take antidepressants during pregnancy… Click here to read full article, “FDA Drug Safety Alert: SSRI / Paxil PPHN.”